A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of parkinson's disease

Gianni Pezzoli, Emilia Martignoni, Claudio Pacchetti, Vita Angeleri, Paolo Lamberti, Alberto Muratorio, Ubaldo Bonuccelli, Michele De Mari, Nicoletta Foschi, Elisabetta Cossutta, Francesco Nicoletti, Giovanni Giammona, Margherita Canesi, Guglielmo Scarlato, Tommaso Caraceni, Elena Moscarelli, S. Fahn, R. Pfeiffer, J. T. Hutton, J. L. MorrisG. Pezzoli, S. Tesei, C. Ferrante, U. K. Rinne, B. Bergamasco, P. Benna, L. Scarzella, M. M. Hoehn, R. L. Elton, P. F. Teychenne, D. Bergsrud, R. L. Elton, R. W. Fuller, J. A. Clemens, M. D. Hynes, D. B. Calne, K. Burton, J. Beckman, M. Gonce, P. J. Delwaide, J. Jankovic, J. I. Sage, R. C. Duvoisin, G. Pezzoli, A. Zecchinelli, C. Mariani, P. A. Le Witt, C. D. Ward, T. A. Larsen, G. Pezzoli, E. Martignoni, C. Pacchetti, A. Lieberman, C. G. Goetz, E. N. Jansen, J. Jankovic, J. Orman, A. Ginanneschi, F. Degl'innocenti, M. T. Maurello, M. Yamadera, G. Ferber, M. Matejcek, W. C. Koller, S. Glatt, B. Vetere-Overfield

Research output: Contribution to journalArticle

Abstract

A single-blind, crossover study was carried out to compare the efficacy and safety of pergolide against that of bromocriptine in 57 patients with Parkinson's disease who showed a declining response to levodopa therapy. Patients were randomly assigned to receive either bromocriptine followed by pergolide, or pergolide followed by bromocriptine. Both drugs were administered for 12 weeks. Patients were assessed by a clinician blinded to treatment assignment using the New York University Parkinson's Disease Scale. The average daily dose of pergolide was 2.3 plus minus 0.8 mg and of bromocriptine 24.2 plus minus 8.4 mg. Addition of pergolide or bromocriptine resulted in a significant improvement in total scores when compared with the previous treatment of levodopa alone (pergolide, p equals 0.0001; bromocriptine, p equals 0.0005). Pergolide was more effective than bromocriptine in daily living scores (p equals 0.02) and motor scores (p equals 0.038). No differences in the incidence of dyskinesias, dystonias, or psychosis were observed between groups. Fewer adverse events were recorded in the pergolide group, and most patients and physicians preferred pergolide to bromocriptine. Pergolide as adjunctive therapy to levodopa was more effective than bromocriptine in this short-term trial.

Original languageEnglish
Pages (from-to)S22-S27
JournalNeurology
Volume45
Issue number3
Publication statusPublished - 1995

Fingerprint

Pergolide
Bromocriptine
Levodopa
Cross-Over Studies
Parkinson Disease
Therapeutics
Parkinson's Disease
Adjunct
Controlled
Single-Blind Method
Dystonia
Dyskinesias
Psychotic Disorders

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Pezzoli, G., Martignoni, E., Pacchetti, C., Angeleri, V., Lamberti, P., Muratorio, A., ... Vetere-Overfield, B. (1995). A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of parkinson's disease. Neurology, 45(3), S22-S27.

A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of parkinson's disease. / Pezzoli, Gianni; Martignoni, Emilia; Pacchetti, Claudio; Angeleri, Vita; Lamberti, Paolo; Muratorio, Alberto; Bonuccelli, Ubaldo; De Mari, Michele; Foschi, Nicoletta; Cossutta, Elisabetta; Nicoletti, Francesco; Giammona, Giovanni; Canesi, Margherita; Scarlato, Guglielmo; Caraceni, Tommaso; Moscarelli, Elena; Fahn, S.; Pfeiffer, R.; Hutton, J. T.; Morris, J. L.; Pezzoli, G.; Tesei, S.; Ferrante, C.; Rinne, U. K.; Bergamasco, B.; Benna, P.; Scarzella, L.; Hoehn, M. M.; Elton, R. L.; Teychenne, P. F.; Bergsrud, D.; Elton, R. L.; Fuller, R. W.; Clemens, J. A.; Hynes, M. D.; Calne, D. B.; Burton, K.; Beckman, J.; Gonce, M.; Delwaide, P. J.; Jankovic, J.; Sage, J. I.; Duvoisin, R. C.; Pezzoli, G.; Zecchinelli, A.; Mariani, C.; Le Witt, P. A.; Ward, C. D.; Larsen, T. A.; Pezzoli, G.; Martignoni, E.; Pacchetti, C.; Lieberman, A.; Goetz, C. G.; Jansen, E. N.; Jankovic, J.; Orman, J.; Ginanneschi, A.; Degl'innocenti, F.; Maurello, M. T.; Yamadera, M.; Ferber, G.; Matejcek, M.; Koller, W. C.; Glatt, S.; Vetere-Overfield, B.

In: Neurology, Vol. 45, No. 3, 1995, p. S22-S27.

Research output: Contribution to journalArticle

Pezzoli, G, Martignoni, E, Pacchetti, C, Angeleri, V, Lamberti, P, Muratorio, A, Bonuccelli, U, De Mari, M, Foschi, N, Cossutta, E, Nicoletti, F, Giammona, G, Canesi, M, Scarlato, G, Caraceni, T, Moscarelli, E, Fahn, S, Pfeiffer, R, Hutton, JT, Morris, JL, Pezzoli, G, Tesei, S, Ferrante, C, Rinne, UK, Bergamasco, B, Benna, P, Scarzella, L, Hoehn, MM, Elton, RL, Teychenne, PF, Bergsrud, D, Elton, RL, Fuller, RW, Clemens, JA, Hynes, MD, Calne, DB, Burton, K, Beckman, J, Gonce, M, Delwaide, PJ, Jankovic, J, Sage, JI, Duvoisin, RC, Pezzoli, G, Zecchinelli, A, Mariani, C, Le Witt, PA, Ward, CD, Larsen, TA, Pezzoli, G, Martignoni, E, Pacchetti, C, Lieberman, A, Goetz, CG, Jansen, EN, Jankovic, J, Orman, J, Ginanneschi, A, Degl'innocenti, F, Maurello, MT, Yamadera, M, Ferber, G, Matejcek, M, Koller, WC, Glatt, S & Vetere-Overfield, B 1995, 'A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of parkinson's disease', Neurology, vol. 45, no. 3, pp. S22-S27.
Pezzoli, Gianni ; Martignoni, Emilia ; Pacchetti, Claudio ; Angeleri, Vita ; Lamberti, Paolo ; Muratorio, Alberto ; Bonuccelli, Ubaldo ; De Mari, Michele ; Foschi, Nicoletta ; Cossutta, Elisabetta ; Nicoletti, Francesco ; Giammona, Giovanni ; Canesi, Margherita ; Scarlato, Guglielmo ; Caraceni, Tommaso ; Moscarelli, Elena ; Fahn, S. ; Pfeiffer, R. ; Hutton, J. T. ; Morris, J. L. ; Pezzoli, G. ; Tesei, S. ; Ferrante, C. ; Rinne, U. K. ; Bergamasco, B. ; Benna, P. ; Scarzella, L. ; Hoehn, M. M. ; Elton, R. L. ; Teychenne, P. F. ; Bergsrud, D. ; Elton, R. L. ; Fuller, R. W. ; Clemens, J. A. ; Hynes, M. D. ; Calne, D. B. ; Burton, K. ; Beckman, J. ; Gonce, M. ; Delwaide, P. J. ; Jankovic, J. ; Sage, J. I. ; Duvoisin, R. C. ; Pezzoli, G. ; Zecchinelli, A. ; Mariani, C. ; Le Witt, P. A. ; Ward, C. D. ; Larsen, T. A. ; Pezzoli, G. ; Martignoni, E. ; Pacchetti, C. ; Lieberman, A. ; Goetz, C. G. ; Jansen, E. N. ; Jankovic, J. ; Orman, J. ; Ginanneschi, A. ; Degl'innocenti, F. ; Maurello, M. T. ; Yamadera, M. ; Ferber, G. ; Matejcek, M. ; Koller, W. C. ; Glatt, S. ; Vetere-Overfield, B. / A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of parkinson's disease. In: Neurology. 1995 ; Vol. 45, No. 3. pp. S22-S27.
@article{a526ab0f63744bcca45f9f712daf58c5,
title = "A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of parkinson's disease",
abstract = "A single-blind, crossover study was carried out to compare the efficacy and safety of pergolide against that of bromocriptine in 57 patients with Parkinson's disease who showed a declining response to levodopa therapy. Patients were randomly assigned to receive either bromocriptine followed by pergolide, or pergolide followed by bromocriptine. Both drugs were administered for 12 weeks. Patients were assessed by a clinician blinded to treatment assignment using the New York University Parkinson's Disease Scale. The average daily dose of pergolide was 2.3 plus minus 0.8 mg and of bromocriptine 24.2 plus minus 8.4 mg. Addition of pergolide or bromocriptine resulted in a significant improvement in total scores when compared with the previous treatment of levodopa alone (pergolide, p equals 0.0001; bromocriptine, p equals 0.0005). Pergolide was more effective than bromocriptine in daily living scores (p equals 0.02) and motor scores (p equals 0.038). No differences in the incidence of dyskinesias, dystonias, or psychosis were observed between groups. Fewer adverse events were recorded in the pergolide group, and most patients and physicians preferred pergolide to bromocriptine. Pergolide as adjunctive therapy to levodopa was more effective than bromocriptine in this short-term trial.",
author = "Gianni Pezzoli and Emilia Martignoni and Claudio Pacchetti and Vita Angeleri and Paolo Lamberti and Alberto Muratorio and Ubaldo Bonuccelli and {De Mari}, Michele and Nicoletta Foschi and Elisabetta Cossutta and Francesco Nicoletti and Giovanni Giammona and Margherita Canesi and Guglielmo Scarlato and Tommaso Caraceni and Elena Moscarelli and S. Fahn and R. Pfeiffer and Hutton, {J. T.} and Morris, {J. L.} and G. Pezzoli and S. Tesei and C. Ferrante and Rinne, {U. K.} and B. Bergamasco and P. Benna and L. Scarzella and Hoehn, {M. M.} and Elton, {R. L.} and Teychenne, {P. F.} and D. Bergsrud and Elton, {R. L.} and Fuller, {R. W.} and Clemens, {J. A.} and Hynes, {M. D.} and Calne, {D. B.} and K. Burton and J. Beckman and M. Gonce and Delwaide, {P. J.} and J. Jankovic and Sage, {J. I.} and Duvoisin, {R. C.} and G. Pezzoli and A. Zecchinelli and C. Mariani and {Le Witt}, {P. A.} and Ward, {C. D.} and Larsen, {T. A.} and G. Pezzoli and E. Martignoni and C. Pacchetti and A. Lieberman and Goetz, {C. G.} and Jansen, {E. N.} and J. Jankovic and J. Orman and A. Ginanneschi and F. Degl'innocenti and Maurello, {M. T.} and M. Yamadera and G. Ferber and M. Matejcek and Koller, {W. C.} and S. Glatt and B. Vetere-Overfield",
year = "1995",
language = "English",
volume = "45",
pages = "S22--S27",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of parkinson's disease

AU - Pezzoli, Gianni

AU - Martignoni, Emilia

AU - Pacchetti, Claudio

AU - Angeleri, Vita

AU - Lamberti, Paolo

AU - Muratorio, Alberto

AU - Bonuccelli, Ubaldo

AU - De Mari, Michele

AU - Foschi, Nicoletta

AU - Cossutta, Elisabetta

AU - Nicoletti, Francesco

AU - Giammona, Giovanni

AU - Canesi, Margherita

AU - Scarlato, Guglielmo

AU - Caraceni, Tommaso

AU - Moscarelli, Elena

AU - Fahn, S.

AU - Pfeiffer, R.

AU - Hutton, J. T.

AU - Morris, J. L.

AU - Pezzoli, G.

AU - Tesei, S.

AU - Ferrante, C.

AU - Rinne, U. K.

AU - Bergamasco, B.

AU - Benna, P.

AU - Scarzella, L.

AU - Hoehn, M. M.

AU - Elton, R. L.

AU - Teychenne, P. F.

AU - Bergsrud, D.

AU - Elton, R. L.

AU - Fuller, R. W.

AU - Clemens, J. A.

AU - Hynes, M. D.

AU - Calne, D. B.

AU - Burton, K.

AU - Beckman, J.

AU - Gonce, M.

AU - Delwaide, P. J.

AU - Jankovic, J.

AU - Sage, J. I.

AU - Duvoisin, R. C.

AU - Pezzoli, G.

AU - Zecchinelli, A.

AU - Mariani, C.

AU - Le Witt, P. A.

AU - Ward, C. D.

AU - Larsen, T. A.

AU - Pezzoli, G.

AU - Martignoni, E.

AU - Pacchetti, C.

AU - Lieberman, A.

AU - Goetz, C. G.

AU - Jansen, E. N.

AU - Jankovic, J.

AU - Orman, J.

AU - Ginanneschi, A.

AU - Degl'innocenti, F.

AU - Maurello, M. T.

AU - Yamadera, M.

AU - Ferber, G.

AU - Matejcek, M.

AU - Koller, W. C.

AU - Glatt, S.

AU - Vetere-Overfield, B.

PY - 1995

Y1 - 1995

N2 - A single-blind, crossover study was carried out to compare the efficacy and safety of pergolide against that of bromocriptine in 57 patients with Parkinson's disease who showed a declining response to levodopa therapy. Patients were randomly assigned to receive either bromocriptine followed by pergolide, or pergolide followed by bromocriptine. Both drugs were administered for 12 weeks. Patients were assessed by a clinician blinded to treatment assignment using the New York University Parkinson's Disease Scale. The average daily dose of pergolide was 2.3 plus minus 0.8 mg and of bromocriptine 24.2 plus minus 8.4 mg. Addition of pergolide or bromocriptine resulted in a significant improvement in total scores when compared with the previous treatment of levodopa alone (pergolide, p equals 0.0001; bromocriptine, p equals 0.0005). Pergolide was more effective than bromocriptine in daily living scores (p equals 0.02) and motor scores (p equals 0.038). No differences in the incidence of dyskinesias, dystonias, or psychosis were observed between groups. Fewer adverse events were recorded in the pergolide group, and most patients and physicians preferred pergolide to bromocriptine. Pergolide as adjunctive therapy to levodopa was more effective than bromocriptine in this short-term trial.

AB - A single-blind, crossover study was carried out to compare the efficacy and safety of pergolide against that of bromocriptine in 57 patients with Parkinson's disease who showed a declining response to levodopa therapy. Patients were randomly assigned to receive either bromocriptine followed by pergolide, or pergolide followed by bromocriptine. Both drugs were administered for 12 weeks. Patients were assessed by a clinician blinded to treatment assignment using the New York University Parkinson's Disease Scale. The average daily dose of pergolide was 2.3 plus minus 0.8 mg and of bromocriptine 24.2 plus minus 8.4 mg. Addition of pergolide or bromocriptine resulted in a significant improvement in total scores when compared with the previous treatment of levodopa alone (pergolide, p equals 0.0001; bromocriptine, p equals 0.0005). Pergolide was more effective than bromocriptine in daily living scores (p equals 0.02) and motor scores (p equals 0.038). No differences in the incidence of dyskinesias, dystonias, or psychosis were observed between groups. Fewer adverse events were recorded in the pergolide group, and most patients and physicians preferred pergolide to bromocriptine. Pergolide as adjunctive therapy to levodopa was more effective than bromocriptine in this short-term trial.

UR - http://www.scopus.com/inward/record.url?scp=0029269745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029269745&partnerID=8YFLogxK

M3 - Article

C2 - 7715793

AN - SCOPUS:0029269745

VL - 45

SP - S22-S27

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 3

ER -